ChinaDrugStatus

Inaticabtagene autoleucel

纳基奥仑赛
Brand: 源瑞达·Oncology / Cell Therapy·Last verified 2026-11-20

CD19 CAR-T therapy retained in the 2026 Commercial List (#13) with an expanded indication scope adding adult relapsed/refractory LBCL alongside r/r B-ALL.

China Approval (NMPA)

Approved
Approval Number(s)
国药准字S20230065
Initial Approval Date
Nov 7, 2023
Notice Published
Nov 8, 2023
MAH
Juventas Cell Therapy Ltd. (合源生物科技股份有限公司)
Approved Scope
Conditional approval for adult relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL); later expanded to adult r/r large B-cell lymphoma (r/r LBCL).

National Reimbursement

Not Listed

Not included in the 2025 or 2026 National Reimbursement Drug List (basic medical insurance).

Commercial Insurance List

Announced · Effective Jan 1, 2027
2026 List Entry
#13 · 源瑞达
Validity Period
2026-01-01 to 2027-12-31
MAH / Authorized Entity
Juventas Cell Therapy Ltd.
Listed Indication Scope
Expanded from 2025 (#11, r/r B-ALL only) to cover both adult r/r B-ALL and adult r/r LBCL (DLBCL NOS, transformed FL, PMBCL) after ≥2 lines of systemic therapy.

Catalog inclusion only. Actual reimbursement depends on individual commercial health insurance policy contracts.

Approved Products, Dosage Forms & Approval Numbers

1 verified NMPA record
Approval No.Dosage Form & StrengthEvent & ScopeApproval / Notice DateMAH & Source
国药准字S20230065
Injection (CAR-T) (注射液)
Initial Approval

Conditional approval for adult relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL); later expanded to adult r/r large B-cell lymphoma (r/r LBCL).

附条件批准用于治疗成人复发或难治性B细胞急性淋巴细胞白血病(r/r B-ALL);后续扩展至成人复发或难治性大B细胞淋巴瘤(r/r LBCL)。

Approved: 2023-11-07
Published: 2023-11-08
Juventas Cell Therapy Ltd.

Change Timeline

  1. (2027-01-01)Commercial List· Catalog published: Nov 14, 2026

    2026 Commercial List · Indication Expanded (#13)

    Expanded from 2025 (#11, r/r B-ALL only) to cover both adult r/r B-ALL and adult r/r LBCL (DLBCL NOS, transformed FL, PMBCL) after ≥2 lines of systemic therapy.

    Chinese original: 本品适用于成人复发或难治性B细胞急性淋巴细胞白血病。本品适用于经过二线或以上系统性治疗后成人复发或难治性大B细胞淋巴瘤,包括:弥漫大B细胞淋巴瘤非特指型、滤泡性淋巴瘤转化的大B细胞淋巴瘤、原发性纵隔大B细胞淋巴瘤。

    NHSA · PDF p.3Verified 2026-11-20
  2. (2026-01-01)Commercial List· Catalog published: Dec 7, 2025

    2025 Commercial List · Listed (#11)

    Adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

    Chinese original: 适用于成人复发或难治性B细胞急性淋巴细胞白血病。

    NHSA · PDF p.3Verified 2026-11-20
  3. (2023-11-07)NMPA Approval· Notice published: Nov 8, 2023

    NMPA Initial Marketing Approval (国药准字S20230065)

    Conditional approval for adult relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL); later expanded to adult r/r large B-cell lymphoma (r/r LBCL).

    Chinese original: 附条件批准用于治疗成人复发或难治性B细胞急性淋巴细胞白血病(r/r B-ALL);后续扩展至成人复发或难治性大B细胞淋巴瘤(r/r LBCL)。

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

纳基奥仑赛注射液dosage name(NHSA)
源瑞达brand zh(NHSA)
CNCT19code(WHO)

Primary Sources for This Record